FoldRx (US-Massachusetts) Drug Class: Small molecule Mechanism/Technology: FoldRx has developed a screening platform that rapidly identifies small molecule modulators of critical pathways of either proteotoxicty or ER-Golgi trafficking. FoldRx’s discovery platform has been applied to a variety of proteins associated with neurodegeneration, including TDP-43 (ALS and Frontal Temporal Lobar Degeneration). Primary Indication: TTR Amyloidosis, PD, HD, Cystic Fibrosis, ALS Stage: Preclinical
